We narrowed to 7,305 results for: plasmid dna

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#111068-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Feb. 25, 2021

Academic Institutions and Nonprofits only

#185386-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#100040-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn1.Twitch2B.WPRE.SV40 (#100040). In addition to the viral particles, you will also receive purified pAAV.hSyn1.Twitch2B.WPRE.SV40 plasmid DNA. Synapsin-driven expression of (FRET)-based calcium biosensor Twitch2B. These AAV preparations are suitable purity for injection into animals.

Oliver Griesbeck

Thestrup et al Nat Methods. 2014 Jan 5. doi: 10.1038/nm

March 8, 2018

Academic Institutions and Nonprofits only

#99039-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

May 15, 2019

Academic Institutions and Nonprofits only

#137126-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-sRGECO (#137126). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-sRGECO plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#137151-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-NpHR3.3-EYFP (#137151). In addition to the viral particles, you will also receive purified pAAV-nEF-NpHR3.3-EYFP plasmid DNA. nEF-driven expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#55638-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#112005-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#217676-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL (#217676). In addition to the viral particles, you will also receive purified pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL plasmid DNA. EF1a-driven, Cre-dependent expression of GtACR2 and soma-targeted Voltron2 (ORCHID). These AAV preparations are suitable purity for injection into animals.

Joseph Raimondo

Selfe et al Nat Commun. 2024 Oct 16;15(1):8913. doi:

Feb. 9, 2026

Academic Institutions and Nonprofits only

#55637-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

March 18, 2024

Academic Institutions and Nonprofits only

#135424-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-jYCaMP1s (#135424). In addition to the viral particles, you will also receive purified pAAV-syn-jYCaMP1s plasmid DNA. Synapsin-driven expression of calcium sensor YCaMP1s. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Mohr et al Nat Methods. 2020 May 25. pii: 10.1038/s

July 22, 2020

Academic Institutions and Nonprofits only

#99130-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Feb. 16, 2024

Academic Institutions and Nonprofits only

#111067-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.1 (#111067). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.1 plasmid DNA. CAG-driven expression of dLight1.1 dopamine sensor. This sensor is recommended for photometry in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

March 12, 2021

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#99130-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 18, 2019

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only